Pfizer defends US Celebrex patents from Teva
World drug giant Pfizer says that a federal court in the District of New Jersey has upheld the three main US patents covering its COX-2 inhibitor Celebrex (celecoxib) used to treat pain and inflammation, which were challenged by Israeli generic manufacturer Teva. The judge in the case ruled that the patents, covering the active ingredient, pharmaceutical composition and method-of-use, are valid, enforceable and infringed by the generic drugmaker's product. The decision, which may be appealed, prohibits Teva from launching a competitor drug in the USA until December 2015. On the day of the news, March 20, Pfizer shares rose 0.7% to $25.54.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze